MLH3-Related Polyposis: Clinical Characterization of a Biallelic Cohort

CGA-IGC 2026

Nov 02, 2026
Oncology
Presentation

Kevin Beezhold, Lucas Zhang, Edward Anderson, Kristin Kohler, Felicia Hernandez, Jennifer Herrera-Mullar

Background and Aim
Despite the identification of genes such as APC, MUTYH, MSH3, and NTHL1 with roles in polyposis and attenuated polyposis, a significant number of cases remain unexplained. Recent literature has proposed MLH3 as a candidate gene for autosomal recessive polyposis; however, a limited number of biallelic carriers have been identified thus far. We sought to further characterize this association by evaluating the clinical phenotypes of biallelic MLH3 carriers within a large clinical laboratory cohort.

 

Methods
We conducted a retrospective, genotype-first review of ~1.5M patients undergoing multigene panel testing (MGPT) from September 2018 through March 2026. Inclusion criteria required the identification of biallelic MLH3 variants. All individuals with truncating or suspicious missense variants selected for further review were negative for pathogenic/likely pathogenic variants in established polyposis genes.

 

Results
We identified seven probands harboring biallelic truncating MLH3 variants. Within this cohort, 71.4% (5/7) reported a history of colonic polyps, and 28.6% (2/7) were diagnosed with colorectal cancer at 50 or younger. Furthermore, four individuals harbored suspicious, rare missense variants. Two were homozygous: one had polyps and CRC, the other polyps and two non-colorectal tumors. The other two were compound heterozygous, with a truncating and missense variant each and a history of colonic polyps. The individuals described above represent approximately 0.0007% of the total cohort observed within the stated timeframe.

 

Conclusions
Our findings provide clinical evidence supporting MLH3 as a driver of autosomal recessive attenuated polyposis. This analysis suggests that MLH3-related polyposis is an exceedingly rare cause of hereditary polyposis. These real-world clinical data help address the limited cohort sizes that have historically constrained evaluation of this rare gene-disease association and support ongoing efforts toward refined gene-disease characterization and variant interpretation.